Partners had an opportunity to get ahead of the curve and position their company at the forefront of the minds of leading pharma and pioneering biotech at the 7th Obesity & NASH Drug Development Summit; dedicated to pushing the boundaries in cutting-edge metabolic research and drug development using contract research, multi-omics, in vivo and in vitro models, digital pathology, artificial intelligence, and non-invasive biomarkers.
Partners had the opportunity to showcase their brand and capitalize on our audience of leading companies with active pipelines in NASH and obesity.